ATE515267T1 - Verwendung eines antikörpers gegen wasserlöslich baff zur krebsbehandlung - Google Patents
Verwendung eines antikörpers gegen wasserlöslich baff zur krebsbehandlungInfo
- Publication number
- ATE515267T1 ATE515267T1 AT03018879T AT03018879T ATE515267T1 AT E515267 T1 ATE515267 T1 AT E515267T1 AT 03018879 T AT03018879 T AT 03018879T AT 03018879 T AT03018879 T AT 03018879T AT E515267 T1 ATE515267 T1 AT E515267T1
- Authority
- AT
- Austria
- Prior art keywords
- cell growth
- immunoglobulin production
- baff
- ligand
- antibody
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 7
- 230000016784 immunoglobulin production Effects 0.000 abstract 5
- 108010028006 B-Cell Activating Factor Proteins 0.000 abstract 4
- 102000016605 B-Cell Activating Factor Human genes 0.000 abstract 3
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 abstract 2
- 210000004443 dendritic cell Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 239000012873 virucide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0325—Animal model for autoimmune diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11716999P | 1999-01-25 | 1999-01-25 | |
| US14322899P | 1999-07-09 | 1999-07-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE515267T1 true ATE515267T1 (de) | 2011-07-15 |
Family
ID=26815006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03018879T ATE515267T1 (de) | 1999-01-25 | 2000-01-25 | Verwendung eines antikörpers gegen wasserlöslich baff zur krebsbehandlung |
| AT00909970T ATE247482T1 (de) | 1999-01-25 | 2000-01-25 | Baff, dessen inhibitoren und dessen verwendung zur modulierung der b-zell-antwort |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00909970T ATE247482T1 (de) | 1999-01-25 | 2000-01-25 | Baff, dessen inhibitoren und dessen verwendung zur modulierung der b-zell-antwort |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6869605B2 (enExample) |
| EP (5) | EP2298332B1 (enExample) |
| JP (5) | JP5066314B2 (enExample) |
| KR (1) | KR100834809B1 (enExample) |
| CN (1) | CN100340292C (enExample) |
| AT (2) | ATE515267T1 (enExample) |
| AU (1) | AU762839B2 (enExample) |
| BR (1) | BR0007719A (enExample) |
| CA (1) | CA2360062A1 (enExample) |
| CY (2) | CY1107453T1 (enExample) |
| CZ (1) | CZ299819B6 (enExample) |
| DE (1) | DE60004635T2 (enExample) |
| DK (2) | DK1415659T3 (enExample) |
| EA (1) | EA006108B1 (enExample) |
| EE (1) | EE05699B1 (enExample) |
| ES (1) | ES2204528T3 (enExample) |
| HK (1) | HK1040628B (enExample) |
| HU (1) | HUP0105283A3 (enExample) |
| IL (3) | IL144202A0 (enExample) |
| IS (1) | IS5993A (enExample) |
| MX (1) | MXPA01007464A (enExample) |
| NO (2) | NO20013641L (enExample) |
| NZ (1) | NZ513284A (enExample) |
| PL (1) | PL198934B1 (enExample) |
| PT (2) | PT1146892E (enExample) |
| SI (1) | SI1146892T1 (enExample) |
| SK (1) | SK286665B6 (enExample) |
| TR (2) | TR200102147T2 (enExample) |
| WO (1) | WO2000043032A2 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| US20030175208A1 (en) * | 1996-10-25 | 2003-09-18 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| US6689579B1 (en) | 1996-10-25 | 2004-02-10 | Human Genome Sciences, Inc. | Polynucleotides encoding neutrokine-α |
| US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
| EP0878552A1 (en) | 1997-05-13 | 1998-11-18 | Erasmus Universiteit Rotterdam | Molecular detection of chromosome aberrations |
| AU3516899A (en) | 1998-05-04 | 1999-11-23 | Dako A/S | Method and probes for the detection of chromosome aberrations |
| GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
| US20050100548A1 (en) * | 2001-07-24 | 2005-05-12 | Biogen Idec Ma Inc. | BAFF, inhibitors thereof and their use in the modulation of B-cell response |
| US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
| CA2360062A1 (en) | 1999-01-25 | 2000-07-27 | Biogen, Inc. | Baff, inhibitors thereof and their use in the modulation of b-cell response |
| US6475987B1 (en) | 1999-05-06 | 2002-11-05 | National Jewish Medical And Research Center | Tall-1 receptor homologues |
| EP1210425B2 (en) | 1999-08-17 | 2015-06-17 | Biogen MA Inc. | Baff receptor (bcma), an immunoregulatory agent |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| PT1255558E (pt) * | 2000-02-16 | 2006-11-30 | Genentech Inc | Anticorpos anti-april e células hibridoma |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| US7879328B2 (en) * | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
| US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
| ATE451390T1 (de) * | 2000-08-18 | 2009-12-15 | Dyax Corp | Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys) |
| US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
| UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
| ES2387546T3 (es) * | 2001-05-11 | 2012-09-25 | Amgen Inc. | Péptidos y moléculas relacionadas que se unen a TALL-1 |
| DK1436003T3 (da) | 2001-05-24 | 2010-03-15 | Zymogenetics Inc | TACI-immunoglobulin-fusionsproteiner |
| KR20040019105A (ko) * | 2001-08-03 | 2004-03-04 | 제넨테크, 인크. | ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도 |
| AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| US7825089B2 (en) | 2001-10-24 | 2010-11-02 | National Jewish Health | Three-dimensional structures of TALL-1 and its cognate receptors and modified proteins and methods related thereto |
| US20080267965A1 (en) * | 2002-02-21 | 2008-10-30 | Kalled Susan L | Use of Bcma as an Immunoregulatory Agent |
| AU2003256836A1 (en) * | 2002-07-25 | 2004-02-16 | Genentech, Inc. | Taci antibodies and uses thereof |
| CN101899106A (zh) | 2002-10-29 | 2010-12-01 | 阿纳福公司 | 三聚细胞因子的三聚结合蛋白 |
| US7553930B2 (en) | 2003-01-06 | 2009-06-30 | Xencor, Inc. | BAFF variants and methods thereof |
| WO2004074511A1 (en) * | 2003-02-21 | 2004-09-02 | Garvan Institute Of Medical Research | Diagnosis and treatment of baff-mediated autoimmune diseases and cancer |
| EP1606312A2 (en) * | 2003-03-07 | 2005-12-21 | Xencor Inc. | Baff mutants with at least one amino acid substitution and methods of their production |
| AU2004233164B2 (en) | 2003-03-28 | 2009-10-08 | Biogen Ma Inc. | Truncated BAFF receptors |
| US20050163775A1 (en) * | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
| EP2272868B1 (en) * | 2003-06-05 | 2015-03-04 | Genentech, Inc. | Combination therapy for B cell disorders |
| MXPA06004301A (es) | 2003-10-20 | 2006-06-05 | Biogen Idec Inc | Regimenes terapeuticos para antagonistas del factor de activacion de celulas b. |
| WO2005075511A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of bcma and uses thereof |
| US20080050381A1 (en) * | 2004-08-31 | 2008-02-28 | Tsutomu Takeuchi | Antihuman Baff Antibody |
| WO2006044582A2 (en) | 2004-10-13 | 2006-04-27 | The Washington University | Use of baff to treat sepsis |
| CA2596276A1 (en) * | 2005-01-28 | 2006-08-03 | Biogen Idec Ma Inc. | Use of baff to treat th2-mediated conditions |
| EP1844069A4 (en) * | 2005-01-28 | 2009-05-20 | Apollo Life Sciences Ltd | MOLECULES AND CHIMESE MOLECULES THEREOF |
| CA2609190A1 (en) * | 2005-05-18 | 2006-11-23 | Biogen Idec Inc. | Methods for treating fibrotic conditions |
| AU2006278227B2 (en) | 2005-08-09 | 2011-10-20 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
| ZA200801354B (en) | 2005-08-09 | 2009-08-26 | Ares Trading Sa | Methods for treating B-cell malignancies using TACI-lg fusion molecule |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
| US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
| EA015342B1 (ru) | 2006-05-15 | 2011-06-30 | Арес Трейдинг С.А. | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig |
| WO2010093993A2 (en) * | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
| BR112012022943A2 (pt) * | 2010-03-11 | 2018-06-05 | Gilead Connecticut Inc | inibidores de syk de imidazopiridnas |
| WO2013171296A1 (en) | 2012-05-16 | 2013-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Diagnostic and treatment of sarcoidosis |
| CZ2012561A3 (cs) * | 2012-08-22 | 2013-10-23 | Masarykova Univerzita | B-bunecný aktivující faktor pro zvýsení sliznicní imunity kojencu a prípravek jej obsahující |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| US9688767B2 (en) | 2013-03-15 | 2017-06-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of predicting survival time in myocardial infarction patients by measuring BAFF levels |
| KR101493592B1 (ko) | 2013-04-29 | 2015-02-17 | 부산대학교 산학협력단 | Ｓｏｃｓ3 단백질을 이용한 ｂａｆｆ 연관 면역질환 치료제 스크리닝 방법 |
| EP3071024B1 (en) | 2013-11-19 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| US10435474B2 (en) | 2013-12-24 | 2019-10-08 | Ossianix, Inc. | Baff selective binding compounds and related methods |
| EA033604B1 (ru) | 2014-01-31 | 2019-11-08 | Boehringer Ingelheim Int | Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид |
| AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
| WO2016205714A1 (en) * | 2015-06-19 | 2016-12-22 | University Of Louisville Research Foundation, Inc. | Immunomodulation for the long term prevention and treatment of autoimmune diseases and foreign tissue rejection |
| CN107328620B (zh) * | 2017-06-23 | 2020-06-05 | 浙江普罗亭健康科技有限公司 | 用于流式细胞技术的封闭缓冲液及试剂盒 |
| WO2019126366A2 (en) * | 2017-12-19 | 2019-06-27 | The Johns Hopkins University | Baff therapy to promote anti- tumor immunity |
| US20210238295A1 (en) * | 2018-04-26 | 2021-08-05 | University Of Virginia Patent Foundation | Compositions and methods for treating abdominal aortic aneurysm |
| KR20210131372A (ko) | 2019-02-22 | 2021-11-02 | 크로노스 바이오, 인코포레이티드 | Syk 억제제로서의 축합된 피라진의 고체 형태 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
| US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| AU726486C (en) | 1996-03-14 | 2004-02-05 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
| US6541224B2 (en) | 1996-03-14 | 2003-04-01 | Human Genome Sciences, Inc. | Tumor necrosis factor delta polypeptides |
| BR9612752A (pt) * | 1996-10-25 | 2000-01-18 | Human Genome Sciences Inc | Neutrocina |
| SE9603950L (sv) | 1996-10-29 | 1997-10-27 | Bjoern Hellstroem | Klämskyddslist |
| WO1998027114A2 (en) * | 1996-12-17 | 1998-06-25 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| CA2232743A1 (en) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
| WO1998055621A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
| AU743490B2 (en) * | 1997-06-06 | 2002-01-24 | Regeneron Pharmaceuticals, Inc. | NTN-2 member of TNF ligand family |
| AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| EA005411B1 (ru) | 1997-09-12 | 2005-02-24 | Апотек Р Энд Д Са | Применение антитела против полипептида april для получения лекарственного препарата для лечения опухолей |
| EA200000311A1 (ru) | 1997-09-12 | 2000-10-30 | Апотек Р Энд Д Са | Новый белок иммунной системы - кау |
| WO1999026463A2 (en) | 1997-11-26 | 1999-06-03 | Eli Lilly And Company | Tnf ligand family gene |
| AU2093499A (en) | 1997-12-30 | 1999-07-19 | Chiron Corporation | Members of tnf and tnfr families |
| US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
| AU1467000A (en) | 1998-11-04 | 2000-05-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A novel tumor necrosis factor family member, drl, and related compositions and methods |
| GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
| DE60005135T3 (de) | 1999-01-07 | 2015-04-09 | Zymogenetics, Inc. | Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung |
| CA2360062A1 (en) * | 1999-01-25 | 2000-07-27 | Biogen, Inc. | Baff, inhibitors thereof and their use in the modulation of b-cell response |
| US6475986B1 (en) | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
| CA2363112A1 (en) | 1999-02-23 | 2000-08-31 | Craig A. Rosen | Neutrokine-alpha and neutrokine-alpha splice variant |
| WO2000050633A1 (en) | 1999-02-24 | 2000-08-31 | The General Hospital Corporation | Method for cloning signal transduction intermediates |
| US6475987B1 (en) | 1999-05-06 | 2002-11-05 | National Jewish Medical And Research Center | Tall-1 receptor homologues |
| CA2399387C (en) * | 2000-02-11 | 2015-11-03 | Biogen, Inc. | Heterologous polypeptide of the tnf family |
| EP2275449B1 (en) | 2000-06-16 | 2016-09-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| AU2001288260A1 (en) | 2000-08-15 | 2002-03-13 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
| EP1456347A4 (en) | 2001-11-16 | 2006-08-02 | Human Genome Sciences Inc | ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE |
-
2000
- 2000-01-25 CA CA002360062A patent/CA2360062A1/en not_active Abandoned
- 2000-01-25 BR BR0007719-4A patent/BR0007719A/pt not_active Application Discontinuation
- 2000-01-25 DE DE60004635T patent/DE60004635T2/de not_active Expired - Fee Related
- 2000-01-25 EP EP10180420.1A patent/EP2298332B1/en not_active Expired - Lifetime
- 2000-01-25 PT PT00909970T patent/PT1146892E/pt unknown
- 2000-01-25 AT AT03018879T patent/ATE515267T1/de active
- 2000-01-25 HK HK02102203.7A patent/HK1040628B/en not_active IP Right Cessation
- 2000-01-25 ES ES00909970T patent/ES2204528T3/es not_active Expired - Lifetime
- 2000-01-25 IL IL14420200A patent/IL144202A0/xx unknown
- 2000-01-25 EP EP00909970A patent/EP1146892B1/en not_active Revoked
- 2000-01-25 SK SK1044-2001A patent/SK286665B6/sk not_active IP Right Cessation
- 2000-01-25 JP JP2000594485A patent/JP5066314B2/ja not_active Expired - Lifetime
- 2000-01-25 AU AU32142/00A patent/AU762839B2/en not_active Expired
- 2000-01-25 PL PL349772A patent/PL198934B1/pl unknown
- 2000-01-25 CN CNB008054878A patent/CN100340292C/zh not_active Expired - Lifetime
- 2000-01-25 EP EP10181337A patent/EP2319527A3/en not_active Ceased
- 2000-01-25 WO PCT/US2000/001788 patent/WO2000043032A2/en not_active Ceased
- 2000-01-25 EP EP15174329.1A patent/EP2974736A1/en not_active Withdrawn
- 2000-01-25 HU HU0105283A patent/HUP0105283A3/hu unknown
- 2000-01-25 TR TR2001/02147T patent/TR200102147T2/xx unknown
- 2000-01-25 EE EEP200100386A patent/EE05699B1/xx unknown
- 2000-01-25 DK DK03018879.1T patent/DK1415659T3/da active
- 2000-01-25 KR KR1020017009356A patent/KR100834809B1/ko not_active Expired - Lifetime
- 2000-01-25 DK DK00909970T patent/DK1146892T3/da active
- 2000-01-25 PT PT03018879T patent/PT1415659E/pt unknown
- 2000-01-25 EA EA200100822A patent/EA006108B1/ru not_active IP Right Cessation
- 2000-01-25 CZ CZ20012696A patent/CZ299819B6/cs not_active IP Right Cessation
- 2000-01-25 NZ NZ513284A patent/NZ513284A/en not_active IP Right Cessation
- 2000-01-25 EP EP03018879A patent/EP1415659B9/en not_active Revoked
- 2000-01-25 MX MXPA01007464A patent/MXPA01007464A/es active IP Right Grant
- 2000-01-25 AT AT00909970T patent/ATE247482T1/de active
- 2000-01-25 SI SI200030207T patent/SI1146892T1/xx unknown
-
2001
- 2001-01-25 TR TR2004/03498T patent/TR200403498T2/xx unknown
- 2001-07-06 IS IS5993A patent/IS5993A/is unknown
- 2001-07-09 IL IL144202A patent/IL144202A/en not_active IP Right Cessation
- 2001-07-24 NO NO20013641A patent/NO20013641L/no not_active Application Discontinuation
- 2001-07-24 US US09/911,777 patent/US6869605B2/en not_active Expired - Fee Related
-
2003
- 2003-11-14 CY CY20031101083T patent/CY1107453T1/el unknown
-
2008
- 2008-11-27 JP JP2008303135A patent/JP4955642B2/ja not_active Expired - Fee Related
-
2009
- 2009-08-20 IL IL200498A patent/IL200498A0/en unknown
-
2011
- 2011-10-05 CY CY20111100946T patent/CY1112458T1/el unknown
-
2012
- 2012-01-24 JP JP2012012379A patent/JP2012087145A/ja not_active Withdrawn
- 2012-03-29 JP JP2012077812A patent/JP2012126749A/ja active Pending
- 2012-04-27 NO NO20120524A patent/NO20120524A1/no not_active Application Discontinuation
-
2014
- 2014-04-24 JP JP2014090152A patent/JP2014141527A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE515267T1 (de) | Verwendung eines antikörpers gegen wasserlöslich baff zur krebsbehandlung | |
| WO2004068931A3 (en) | Amphiregulin antibodies and their use to treat cancer and psoriasis | |
| ATE348808T1 (de) | Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten | |
| ATE212038T1 (de) | Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung | |
| ATE541860T1 (de) | Humane antikörper gegen cd40 zur therapie von b- zell tumoren | |
| WO2005044854A3 (en) | Antagonist anti-cd40 monoclonal antibodies and methods for their use | |
| DE60030889D1 (de) | Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs | |
| DE602004028643D1 (de) | Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens | |
| RU2008128244A (ru) | Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2 | |
| ATE362491T1 (de) | Induktion der anti-tumor-ctl-immunität durch in- vivo-aktivierung von 4-1bb und/oder cd40 | |
| EP1684805B8 (en) | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma | |
| DE69517054D1 (de) | Verwendung von inhibitoren des rezeptors der von blutplättchen abstammenden wachstumsfaktoren zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| MX342777B (es) | Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa. | |
| ATE225167T1 (de) | Verwendung von inhibitoren der synthese von fettsäuren zur behandlung von krebs | |
| ATE402257T1 (de) | Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit | |
| DE60224299D1 (de) | Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor | |
| CA2356009A1 (en) | Vascular endothelial growth factor-x | |
| GB9907048D0 (en) | Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders | |
| CY1108781T1 (el) | Εμβολιο ψαριων | |
| ATE298244T1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen | |
| RU95106637A (ru) | Способ хирургического лечения злокачественных опухолей головного мозга |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEFA | Change of the company name | ||
| UEP | Publication of translation of european patent specification |
Ref document number: 1415659 Country of ref document: EP |